Compare · FARO vs TMO
FARO vs TMO
Side-by-side comparison of FARO Technologies Inc. (FARO) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FARO and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.52B, about 186.2x FARO ($937.3M).
- Over the past year, FARO is up 3.7% and TMO is up 14.9% - TMO leads by 11.2 points.
- TMO has hit the wire 17 times in the past 4 weeks while FARO has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 4 for FARO).
- Company
- FARO Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $43.99+0.42%
- $469.56-0.67%
- Market cap
- $937.3M
- $174.52B
- 1M return
- +0.50%
- -1.03%
- 1Y return
- +3.68%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 0
- 17
- Recent ratings
- 4
- 25
FARO Technologies Inc.
FARO Technologies, Inc. designs, develops, manufactures, markets, and supports software driven three-dimensional (3D) measurement, imaging, and realization solutions worldwide. It operates through three segments: 3D Manufacturing, Construction BIM, and Emerging Verticals. The company offers FaroArm, a combination of a portable articulated measurement arm, a computer, and CAM2 software programs; FARO Laser Projector, which provides a virtual template that operators and assemblers can use to quickly and accurately position components; and FARO Focus laser scanner to measure and collect a cloud of data points. In addition, the company offers FARO ScanPlan, a handheld mapper that captures two-dimensional floor plans; and FARO Software, a family of computer-aided design-based measurement and laser scanner software. FARO Technologies, Inc. offers its products for metrology, reverse engineering, factory automation, building information modeling, public safety, and other applications. FARO Technologies, Inc. was founded in 1981 and is headquartered in Lake Mary, Florida.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest FARO
- A New Era Unfolds: FARO and Creaform Combine to Form Two New Business Units
- SEC Form 15-12G filed by FARO Technologies Inc.
- Amendment: FARO Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form EFFECT filed by FARO Technologies Inc.
- Director Wasserman Yuval returned $6,937,876 worth of shares to the company (157,679 units at $44.00), closing all direct ownership in the company (SEC Form 4)
- Director Van Rotterdam Jeroen returned $1,932,480 worth of shares to the company (43,920 units at $44.00), closing all direct ownership in the company (SEC Form 4)
- Director Ramanathan Rajani returned $1,289,376 worth of shares to the company (29,304 units at $44.00), closing all direct ownership in the company (SEC Form 4)
- President and CEO Lau Peter James returned $7,043,344 worth of shares to the company (160,076 units at $44.00), closing all direct ownership in the company (SEC Form 4)
- SVP & Chief Financial Officer Horwath Matthew returned $1,727,616 worth of shares to the company (39,264 units at $44.00), closing all direct ownership in the company (SEC Form 4)
- Director Donofrio John returned $3,014,132 worth of shares to the company (68,503 units at $44.00), closing all direct ownership in the company (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)